Month: September 2026

NEW YORK, NY, Sept. 17, 2026 (GLOBE NEWSWIRE) — Host Digital Inc. (f/k/a Healthy Choice Wellness Corp.) (NYSE American: HCWC) (the “Company” or “Host Digital”) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 2,187,500 shares of its Class A common stock, par value $0.001 (the “Common Stock”), at a public offering price of $8.00 per share, for aggregate gross proceeds to the Company of $17.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Offering is expected to close on September 21, 2026, subject to the satisfaction of customary closing conditions.

The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 328,125 shares of its Common Stock at the public offering price, less underwriting discounts and commissions.

The Company intends to use the net proceeds from the Offering for data center investments, general and administrative expenses, capital expenditures, working capital and other general corporate purposes

Cantor is acting as lead book-running manager for the Offering. Siebert, A.G.P. and Clear Street are acting as joint book-running managers for the Offering.

The Offering is being made by means of a prospectus supplement under the Company’s effective registration statement on Form S-3 (File No. 333-291258), as filed with the Securities and Exchange Commission (the “SEC”). A final prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the Offering may also be obtained, when available, from Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

No Offer or Solicitation

This press release is not intended to be, and shall not constitute, an offer to buy or sell, or the solicitation of an offer to buy or sell, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under applicable securities laws. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

About Host Digital Inc.

Host Digital is a digital infrastructure company focused on the development, acquisition, ownership and operation of institutional-quality data centers in the United States, with a focus on supporting artificial intelligence (“AI”) and high-performance computing (“HPC”) workloads. The Company’s strategy prioritizes sites with existing or near-term access to power, right-sized development opportunities and long-term contracts with strong or credit-enhanced counterparties. The Company seeks to own and control the real estate, power and data center infrastructure underlying its projects and to provide turnkey facilities that allow tenants to select and deploy their own compute infrastructure and model layers.

Following its business combination with Host Digital Infrastructure LLC, the Company also owns and operates a portfolio of natural and organic grocery stores through its wholly owned subsidiaries, consisting of 19 locations across six states operating under the Ada’s Natural Market, Paradise Health & Nutrition, Mother Earth’s Storehouse, Greens Natural Foods, Ellwood Thompson’s and GreenAcres Market brands.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed Offering, including the anticipated closing date of the Offering; the anticipated use of proceeds from the Offering; the potential exercise by the underwriters of their option to purchase additional shares; and the Company’s ability to execute and scale its business model. Statements that are not historical facts are based on current estimates, assumptions and projections and are not guarantees of future performance. Words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “will,” “would,” “could” and similar expressions identify forward-looking statements, although not all forward-looking statements contain these words.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks relating to the completion of the Offering on the anticipated terms or at all; the Company’s ability to satisfy the applicable listing requirements; the Company’s ability to successfully integrate the businesses and realize the anticipated benefits of the Offering; the Company’s ability to obtain required financing, complete development and deliver capacity on schedule; and other factors described in the Company’s filings with the SEC. The Company undertakes no obligation to update these statements except as required by law.

Contact Information

Jessica Starman
jessica@elev8newmedia.com
888-461-2233

SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the closing of its previously announced public offering of an aggregate 4,322,489 Class A Ordinary Shares (“the Offering”) at a price of $1.15 per share (“the Offering Price”) to the public, for a total of approximately $4.97 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.

The Company has granted the underwriter a 45-day option to purchase up to an additional 648,373 shares of its Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (“the Over-allotment”). Assuming that the Over-allotment is exercised, the Company is expected to receive gross proceeds amounting to approximately $5.72 million, before deducting underwriting discounts and commissions and estimated offering expenses.

The Company intends to use net proceeds from the Offering for expansion into new businesses, R&D activities to expand its product offerings, growth and expansion into new markets, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes.

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Ellenoff Grossman & Schole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.

“We thank our new and existing shareholders for their support in this Offering,” said David Quek, Chief Executive Officer of Cuprina. “The Offering comes at an important stage for the Company, following U.S. FDA 510(k) clearance for MEDIFLY Maggots™ in June. We intend to use the net proceeds as described in our prospectus, including building out our new business collaborations, advancing our wound care pipeline, and expanding into new markets.”

“Chronic wounds remain the core of our business. We believe demand for effective wound care will keep growing as populations age and rates of diabetes, obesity, cardiovascular disease and peripheral vascular disease rise. We also believe our approach, which uses materials derived from natural sources, positions Cuprina to meet that need, and we look forward to updating shareholders on our progress.”

The Offering is being conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-297299) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on September 15, 2026. The Offering is being made only by means of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. Copies of the final prospectus related to the Offering may be obtained, when available, from R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the gross proceeds of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The gross proceeds to Electra from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Electra, are expected to be approximately $350.0 million. In addition, Electra has granted the underwriters a 30-day option to purchase up to an additional 3,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Electra.

The shares are expected to begin trading on The Nasdaq Global Select Market on September 18, 2026, under the ticker symbol “ETRA.” The offering is expected to close on September 21, 2026, subject to the satisfaction of customary closing conditions.
Jefferies, TD Cowen, Evercore ISI and Cantor are acting as joint book-running managers for the offering.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 17, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by email at ecm.prospectus@evercore.com or by telephone at (888) 474-0200; or Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Electra Therapeutics

Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function. The company’s lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory T-cell and natural-killer cell malignancies. ELA822, the company’s second clinical-stage product candidate, is a novel SIRPγ-specific antibody being developed for a broad range of chronic T cell-mediated immune and inflammatory diseases.

Contacts:

Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com

Media Contact:
Sara Sutton, THRUST
sarah@thrustsc.com